This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.

Inclusion Criteria: * Histologic or cytologic confirmation of NSCLC (locally advanced or metastatic, IB-IV) * Failure of first-line platinum-based chemotherapy Exclusion Criteria: * Mixed small cell or non-small-cell histology * Bronchoalveolar carcinoma * Prior chemotherapy or herbal preparations must be discontinued more than 4 weeks before the start of study therapy (6 weeks for nitrosoureas, mitomycin and suramin) * Prior treatment with docetaxel